Online ISSN: 3007-0244,
Print ISSN:  2410-4280
RETROSPECTIVE ANALYSIS OF CHARACTERISTICS OF PATIENTS WITH CHRONIC HEPATITIS B
Introduction. Hepatitis B virus infection is widespread, progressive, and therefore presents a serious global problem. The infection can develop into a chronic form with a high risk of death from cirrhosis and liver cancer. Kazakhstan is country with high endemicity for the spread of this infection. Objective: To determine the main demographic, clinical, laboratory, serological characteristics of chronic hepatitis B patients. Materials and methods. This retrospective cohort study was conducted using medical records of patients with chronic hepatitis B. A total of 239 participants were enrolled. Enrolled patients had a long-term follow-up with several blood analyzed over time. Characterize of the patients was taken into account: the demographic and clinical-laboratory features, risk factors, and antiviral treatment. Results: Chronic hepatitis B in our environment occurs mainly in married educated employed middle-aged persons. The prevalence of chronic forms of cholecystitis, pancreatitis, bronchitis was increased with age (p<0.001). Male patients had higher serum ALT at baseline (57.5 (31.48-95.8) U/L and during follow-up (at 6 months, 12 months, 18 months and 84 months). An HBsAg decline was observed from baseline and during follow-up. There is significant difference in HBsAg at 18 months between male and female, 3.80 (3.12-6.42) log IU/mL and 2.79 (1.76-3.28) log IU/mL, respectively (p<0.05). The majority of patients had dental treatment (90%), surgery operations (59,83%), in particular appendectomy and gynecological interventions. 26,8% and 23,43% of patients had beauty procedures and Hepatitis A during early childhood, respectively. Conclusion: Portrait of the Chronic hepatitis B patient was formed. The management of these patients should take into consideration age, gender, comorbidities and risk factors. Characteristics of the patients can be one of the essential keys for timely diagnosis and formation of risk groups, also in patient’s treatment and its adherence. This data can be vital in the development of preventive measures among the general population.
Saniya B. Saussakova1, https://orcid.org/0000-0003-0394-5117 Assiya K. Turgambayeva1, https://orcid.org/0000-0002-2300-0105 Zhandulla Nakipov1, https://orcid.org/0000-0001-5528-693X Gaukhar Dauletova1, https://orcid.org/0000-0002-1621-8149 Karlygash Tebenova2, https://orcid.org/0000-0003-0648-7828 1 NCJSC «Astana Medical University», Department of Public Health and Management, Astana, Republic of Kazakhstan; 2 Academician E.A. Buketov Karaganda University, Department of Special and Inclusive Education, Karaganda, Republic of Kazakhstan.
1. Alghamdi A.S., Alothmani H.S., Mogharbel M. et al. Clinical Characteristics of Hepatitis B Virus Patients After Switching to Tenofovir Alafenamide Fumarate: A Retrospective Observational Study // Cureus. 2020. 12(9):e10380. DOI: 10.7759/cureus.10380. PMID: 33062501; PMCID: PMC7550005. 2. Ali K.M., Haider M.S., Nusrat B. et al. Demographics, Biochemical Characteristics, and Phases of Chronic Hepatitis B Virus Infection: Retrospective Analysis From a Secondary Care Setup // Cureus. 2021. 13(7):e16558. DOI: 10.7759/cureus.16558. PMID: 34430162; PMCID: PMC8380003. 3. Baig S. Gender disparity in infections of Hepatitis B virus // J Coll Physicians Surg Pak. 2009. 19(9):598-600. PMID: 19728952. 4. Bao X., Guo J., Xiong F. et al. Clinical characteristics of chronic hepatitis B cured by peginterferon in combination with nucleotide analogs // Int J Infect Dis. 2020. 96:562-566. DOI: 10.1016/j.ijid.2020.05.041. Epub 2020 May 29. PMID: 32474201. 5. Bektayeva R.R., Bekenova F.K. et al. Epidemiological aspects of chronic viral hepatitis B in various regions of the Republic of Kazakhstan // Medicine (Almaty). 2017. 9 (183):109-113. 6. Berkinbayev S.F., Dzhunusbekova G.A., Nersesov A.V. et al. Prevalence of viral hepatitis among residents of Almaty city and Almaty region // Medicine (Almaty). 2017. 8 (182):41-46. 7. Chan H.L., Thompson A., Martinot-Peignoux M. et al. Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report // J Hepatol. 2011. 55:1121–31. doi:10.1016/jhep.2011.06.006. 8. Dakhil N., Junaidi O., Befeler A.S. Chronic viral hepatitis // Mo Med. 2009. 06(5):361-5. 9. Department of Public Health Protection. Annual report // Astana: Informburo. 2019. 1 р. 10. European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection // J Hepatol. 2017. 67:370–98. 11. Gu J., Yu G., Zhang X. et al. Cross-sectional retrospective analysis of clinical characteristics of chronic hepatitis B patients with oral antiviral treatment in eastern China // Virol J. 2021. 18(1):19. DOI: 10.1186/s12985-021-01491-6. PMID: 33441170; PMCID: PMC7805123. 12. Hamida M.E., Raja S.M., Seyoum Y. et al. Prevalence of chronic hepatitis B phases in Eritrean patients: a laboratory-based cross-sectional study // BMC Gastroenterol. 2021. 21(1):198. DOI: 10.1186/s12876-021-01789-3. PMID: 33933017; PMCID: PMC8088660. 13. Hui C.K., Leung N., Yuen S.T., et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase // Hepatology. 2007. 46:395–401. 14. IBM Corp. Released 2015. IBM SPSS Statistics for Windows, Version 23.0 // Armonk, NY: IBM Corp. 15. Liang X., Bi S., Yang W., Wang L. et al. Reprint of: Epidemiological serosurvey of Hepatitis B in China —Declining HBV prevalence due to Hepatitis B vaccination // Vaccine. 2013. 31:J21–J8. DOI:10.1016/j.vaccine.2013.08.012 PMID: 23948229. 16. Liaw Y.F., Leung N., Guan R. et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update // Liver Int. 2005. 25:472–89. 17. Liaw Y.F. Asia-Pacific Steering Committee Members. Chronic hepatitis B: treatment alert // Liver Int. 2006. 26:47–58. 18. Liu WC, Liu QY. Molecular mechanisms of gender disparity in hepatitis B virus-associated hepatocellular carcinoma // World J Gastroenterol. 2014. 20(20):6252-61.doi: 10.3748/wjg.v20.i20.6252. PMID: 24876746; PMCID: PMC4033463. 19. Lok A.S., Mc Mahon B.J. Chronic hepatitis B // Hepatology. 2007. 45:507–39. 20. Lu J.B., Cai S.H., Pan Y.H., Yun J.P. Altered epidermal fatty acid-binding protein expression in hepatocellular carcinoma predicts unfavorable outcomes // Cancer Manag Res. 2018. 10:6275-6284. DOI:10.2147/CMAR.S181555. 21. Nersesov A., Gusmanov A., Crape B. et al. Seroprevalence and risk factors for hepatitis B and hepatitis C in three large regions of Kazakhstan // PLoS ONE. 2021. 16(12):e0261155. DOI:10.1371/journal.pone.0261155. 22. Nguyen M.H., Lim J.K., Burak Ozbay A. et al. Advancing age and comorbidity in a US insured populationbased cohort of patients with chronic hepatitis B // Hepatology. 2019. 69(3):959–73. 23. Ormeci A., Aydın Y., Sumnu A. et al. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels // Int J Infect Dis. 2016. 52:68-73. DOI: 10.1016/j.ijid.2016.09.007. Epub 2016 Sep 9. PMID: 27619844. 24. Ospanova E.N., Amantay Y., Imanova D.N. et al. Background of hepatitis B focal infection rise among immunized population // Life Science Journal. 2014. 11 (4):294–6. 25. Ott J., Stevens G., Groeger J., Wiersma S. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity // Vaccine. 2012. 30(12):2212–9. DOI:10.1016/j.vaccine.2011.12.116 PMID: 22273662. 26. Poorolajal J., Majdzadeh R. Prevalence of chronic hepatitis B infection in Iran: a review article // J Res Med Sci. 2009. 14:249–58. 27. Qureshi H., Javaid N., Alam S.E., Bile K.M. The evidence of mother to child transmission of hepatitis B virus infection in Pakistan and the need for hepatitis B immunization policy change // J Pak Med Assoc. 2014. 64(4):403-8. PMID: 24864633. 28. Ryder S.D., Beckingham I.J. ABC of diseases of liver, pancreas, and biliary system: Acute hepatitis // BMJ. 2001. 322(7279):151-3. 29. Sakupova G.A., Glushkova N.Y., Sulejmenova Z.N., et al. Analysis of the long-term dynamics of the incidence of viral hepatitis B and C in the territory of the Republic of Kazakhstan (retrospective analysis) // Nauka i Zdravookhranenie. 2021. 23(4):163-171. DOI: 10.34689/SH.2021.23.4.018. 30. Sarin S.K., Kumar M., Lau G.K. et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update // Hepatol Int. 2016. 10(1):1-98. DOI:10.1007/s12072-015-9675-4. 31. Shepard C.W., Simard E.P., Finelli L., et al. Hepatitis B virus infection.: epidemiology and vaccination// Epidemiologic reviews. 2006. 28(1):112–25. DOI:10.1093/epirev/mxj009 PMID: 16754644. 32. Talagatkyzy Zh., Arykpayeva U.T., Suleimenova R.K., Abildayeva A.K. Epidemiological features of HBV transmission for the period 2008-2012 and 2015 in the capital region // Collection of the International scientific and practical conference of students and young scientists. 2020. 1:72-73. 33. Terrault N.A., Lok A.S.F., McMahon B.J., et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance // Hepatology. 2018. 67:1560–99. 34. Wong G.L., Wong V.W., Yuen B.W. et al. An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory-Wide Study From 2000 to 2017 // Hepatology. 2020. 71(2):444-455. DOI: 10.1002/hep.30833. Epub 2019 Aug 13. PMID: 31237366. 35. World Health Organization. Global Hepatitis Report 2017 // Geneva: World Health Organization. 2017. 83 p. 36. World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. Geneva: World Health Organization. 2016. 56 p. 37. World Health Organization. Kazakhstan: WHO statistical profile // Geneva: World Health Organization; 2022. Available from: http://www.euro.who.int/en/countries/kazakhstan 38. Yang J., Hall K., Nuriddin A., Woolard D. Risk for hepatitis B and C virus transmission in nail salons and barbershops and state regulatory requirements to prevent such transmission in the United States // J Public Health Manag Pract. 2014. 20(6):E20-30. DOI: 10.1097/PHH.0000000000000042. 39. Yotsuyanagi H., Kurosaki M., Yatsuhashi H. et al. Characteristics and Healthcare Costs in the Aging Hepatitis B Population of Japan: A Nationwide Real-World Analysis // Dig Dis. 2022. 40(1):68-77. DOI: 10.1159/000515854. Epub 2021 Mar 15. PMID: 33721872. 40. Yushchuka N.D., Vengerova Y.Y. Infectious diseases: national guidelines. Moscow: GEOTAR-Media. 2010. 1056 p. 41. Yushchuka N.D., Vengerova Y.Y. Infectious diseases: national guidelines // Moscow: GEOTAR-Media; 2014. 1607 p. 42. Zhang S., Ma Q., Liang S. et al. Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China // Journal of viral hepatitis. 2016. 23(3):202–10. DOI:10.1111/jvh.12482 PMID: 26663525.
Количество просмотров: 320

Ключевые слова:


Библиографическая ссылка

Saussakova S.B., Turgambayeva A.K., Nakipov Zh., Dauletova G., Tebenova K. Retrospective analysis of characteristics of patients with chronic hepatitis B // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 1, pp. 86-93. doi 10.34689/SH.2023.25.1.011

Авторизируйтесь для отправки комментариев